Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan

Published:2017 Issue:6 Volume:58 Page:847-852
ISSN:1349-2365
Container-title:International Heart Journal
language:en
Short-container-title:Int. Heart J.

Author:

Kodera Satoshi¹,Kiyosue Arihiro¹,Ando Jiro¹,Akazawa Hiroshi¹,Morita Hiroyuki¹,Watanabe Masafumi¹,Komuro Issei¹

Affiliation:

1. Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo

Publisher

International Heart Journal (Japanese Heart Journal)

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/ihj/58/6/58_17-365/_pdf

Reference47 articles.

1. 1. Weinstein MC, Skinner JA. Comparative effectiveness and health care spending-implications for reform. N Engl J Med 2010; 362: 460-5.

2. 2. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009; 302: 1437-43.

3. 3. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010; 182: E839-42. (Review).

4. 4. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford, England: Oxford University Press; 2015.

5. 5. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016; 316: 1093-103.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 inhibition: from effectiveness to cost-effectiveness;Frontiers in Cardiovascular Medicine;2024-06-25

2. Empagliflozin cost‐effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction;ESC Heart Failure;2023-11-15

3. Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial;Journal of Cardiology;2023-06

4. Commentary: Beyond 10-year risk: A cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease;Frontiers in Cardiovascular Medicine;2022-07-22

5. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction;American Journal of Cardiovascular Drugs;2022-07-07